About ResMed

“Our new brand will be front and center as we continue making a difference to patients, to physicians, and to healthcare systems. It’s exciting and it’s just the first step in what will be a landmark year for ResMed, with launches of game-changing products and solutions.”

Mick Farrell, CEO ResMed

The executive team

At ResMed, we believe that every breath is a gift. And from the day we began pioneering sleep apnea treatment in 1989, our purpose has been to spread awareness and deliver life-changing products and solutions to patients suffering from sleep-disordered breathing and other respiratory conditions.

More than thirty years later, we’re unveiling a new brand that reinforces our stance as an industry leader and, more importantly, our commitment to improving lives.
To reflect our updated brand, we’ve refreshed our company website for the US and updated our logo.

The blue-to-red pulse curve not only symbolizes the transition from deoxygenated to oxygenated blood with every breath and beat of the heart, but it represents the very reason we are here today as an organization; to make every breath another chance for positive change.

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases.
ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 7,500-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 140 countries.

Our strategy is to change 250 million lives in 2025. We’re proud to make equipment and connected health solutions that give those with sleep apnea, COPD and other respiratory diseases the gift of breath.

Aims and objectives

Our aim is to deliver life-changing products and connected health solutions to patients worldwide with sleep apnea or other respiratory conditions, and to spread awareness about these conditions and treatments. Our objective is two-fold:

1. Provide life-changing diagnoses and treatments to patients with sleep apnea, COPD and other respiratory diseases; and
2. Enable remote and self-monitoring via our therapy devices to improve patients’ experiences, outcomes and health, as well as clinicians’ patient management efficiency.

We sell a comprehensive range of products in more than 140 countries worldwide through direct offices and a network of distributors. Plus more than 11 million ResMed devices are cloud-connected, sharing actionable data with clinicians and patients themselves to improve their therapy experience, adherence and overall health.

Dedicating 7 percent of annual revenue to research and development, we are committed to advancing innovative technology in sleep and respiratory medicine, to commercializing innovative products that incorporate these technologies around the world, and exercising the highest standards of ethics and quality at all times.

“You’ve got to be passionate about something to make it happen in the right way.” ResMed Founder and Executive Chairman Peter Farrell

ResMed’s story began in 1981 when University of Sydney professor Colin Sullivan and his colleagues invented the continuous positive airway pressure or CPAP device, the first successful non-invasive treatment for obstructive sleep apnea (OSA).

Prototype in hand, Sullivan now needed a global manufacturer. In 1986 he approached Chris Lynch, managing director of the Baxter Centre for Medical Research and vice president of R&D for Baxter Healthcare. Lynch told his coworker Dr. Peter Farrell that he should talk to Sullivan, who just “developed a way to treat snoring sickness with a reverse vacuum cleaner.”

Back then, CPAP masks had to be glued onto the face each night. When Farrell asked a patient why he didn’t mind the procedure, he replied “This device has saved my job, my marriage, and my life.” Convinced of CPAP’s worth, Farrell believed the system could be made smaller, quieter, and lighter, spurring global adoption.

In 1987 Farrell, on behalf of Baxter, invested in Sullivan’s CPAP and began clinical trials on a group of patients with severe sleep apnea.

After two years, Baxter decided not to pursue CPAP further. Farrell saw its immense value, bought the technology off Baxter for A$1.2 million, and founded ResCare (short for “Respiratory Care”) to bring CPAP to the world at large. (The company changed its name to ResMed [for “Respiratory Medicine”] in 1995.)

Today, CPAP remains the gold standard treatment for sleep apnea, which over 936 million people live with worldwide. (Over 80 percent are undiagnosed.).

A global medtech leader, ResMed has sold over 11 million 100% cloud connectable sleep devices worldwide that have recorded over 5 billion nights of user data. The insights from this data help clinicians support patients remotely and guide them toward better sleep and health. Large-scale researchers also use them to uncover new best practices for helping whole populations succeed on long-term therapy.

Over 2.5 million people also track their own CPAP device use on ResMed’s myAir app. Up to 87 percent of CPAP users who are both remotely and self-monitored are adherent to therapy, compared to roughly 50 percent on non-cloud connected devices.

ResMed also offers a full suite of products to hundreds of millions living with COPD (chronic obstructive pulmonary disease) and lung disease: portable oxygen, cloud connectable in-home life support ventilators, and inhaler sensors from Propeller Health that help track and improve inhaler use (for those with COPD and asthma).

In addition to life-changing home medical devices, ResMed has built a software-as-a-service ecosystem designed to help millions navigate out-of-hospital healthcare services that traditionally have been siloed and difficult to move between. ResMed’s SaaS ecosystem spans 7 out-of-hospital sectors: home medical equipment, skilled nursing, life plan communities, home health, hospice, senior living, and private duty.

Today, ResMed employs more than 7,500 people around the world and sells products in more than 140 countries. While ResMed’s journey and success have been extraordinary, as ResMed’s CEO Mick Farrell often says, “This is a marathon, and we are only just lacing our shoes.”

Join with us and follow our journey to the next decade and beyond as we empower millions to sleep, breathe, and live better in the comfort of their own home or the care setting of their choice.

ResMed’s mission statement

ResMed changes lives by developing, manufacturing and distributing innovative medical devices and cloud-based software solutions to better diagnose, treat, and manage sleep-disordered breathing, COPD, and other key chronic diseases.

Responsibility

All levels of management and employees are responsible for minimizing the impact of ResMed’s operations on the environment.

Environmental policy statement

ResMed is committed to working with our employees, suppliers and customers to protect the environment and in doing so to systematically reduce our costs. We aim to achieve this by:

• Eliminating unnecessary waste in all our systems & processes, such as minimizing our use of natural resources
• Minimizing our pollution, in particular our non-biodegradable waste to landfill
• Designing and developing products with reduced impact on the environment throughout their lifecycle.
• Increasing our employees’ awareness of the environmental impacts of their decisions and actions
• Monitoring our environmental performance and collaborating with employees, suppliers, customers and regulatory bodies to make continual improvements
• Fulfilling our compliance obligations including applicable federal, state, local laws and regulations, as well as relevant international programs aimed at reducing harmful pollutants